Autopsy report · NCT02534038
Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition
Cause of deathSlow enrollment
“The study was terminated prematurely because of difficulty with recruiting.”
Life of this trial
- Registered 4 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 3 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Industry
- Conditions
- Disinhibition Syndrome
- Interventions
- AVP-786; Placebo
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer
“The study was terminated early as it failed to recruit.” - Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell Transplantation
“Study terminated prematurely due to poor recruitment.” - To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
“the study was early terminated due to lack of recruitment.” - Alfuzosin Versus Placebo in Acute Urinary Retention
“The study was early terminated due to slow and difficult recruitment” - Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children
“Due to low recruitment numbers, the study was terminated.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.